CELG News and Press, Celgene Corporation From 10/08/19

Market volatility is increasing and that's resulting in some interesting opportunities investors can consider. There's no telling what stocks will pop or drop the most from here; however, it's clear from our most recent research that investors are increasingly focusing on defensive stocks, rat...

Merck’s (NYSE: MRK ) Keytruda cancer drug will be the world's best selling drug by 2025 , with projected annual sales of $22.5B, according to a new report from the GlobalData research firm. More news on: Merck & Co., Inc., AbbVie Inc., Bristol-Myers Squibb Company, Healthc...

Bristol-Myers Squibb ( BMY ) is a large-cap ($82 billion), diverse pharmaceutical company that has been in the news due to its planned merger with Celgene ( CELG ). Bristol-Myers Squibb derives about two-thirds of its revenue from two of its drugs, the cancer therapy Opdivo and the anticoagula...

Merger activity decreased last week with one new deal announced and six deals closing. Deal Statistics: New Deals: The acquisition of Arotech Corporation ( ARTX ) by Greenbriar Equity Group for $100 million or $3.00 per share in cash. Deal Updates: On September 23, 2019,...

Investing in growth stocks can feel like a roller-coaster ride. For instance, at the beginning of the year,  Ionis Pharmaceuticals (NASDAQ: IONS) was trading at $52 a share. By April, the stock was up to $86 a share. And now it's back down to $59. That's a fair amount of volatility! Indi...

You might think that biotech stocks are risky and volatile. And they often are. But biotech stocks overall have handily beaten the S&P 500 index over the last 10 years. With exciting new drugs potentially on the way, the next decade could be just as profitable for biotech investors. Whi...

While investors often covet growth stocks, it's dividend stocks that are usually the heart and soul of any successful long-term portfolio . That's because income stocks bring a host of comparative advantages to the table that can't be beat. For one, dividend stocks have a history of outperform...

You might have run across headlines in recent months about how Amgen (NASDAQ: AMGN) is too cheap of a stock to ignore. I've seen several articles that trumpeted the big biotech's attractive valuation. If you look at Amgen's forward price-to-earnings (P/E) ratio of 12.4, the stock indeed doe...

Getting new drugs to market can be a tough business. Acceleron Pharma (NASDAQ: XLRN) is learning this the hard way, scrapping plans to continue development for its experimental drug, ACE-083, in treating patients who have facioscapulohumeral muscular dystrophy (FSHD).  The drug showed ...

Quick Take ADC Therapeutics ( ADCT ) intends to raise $200 million in an IPO of its common shares, per an F-1/A registration statement . The company is developing a pipeline of drug treatment candidates for various blood cancers and solid tumors. ADCT has shown promising trial results a...